GlobeNewswire

Novastra Therapeutics Establishes Scientific Advisory Board and Appoints Senior Advisors and Head of Clinical Development
05/11/2026
Experts in immuno-oncology, medical oncology, clinical development, and regulatory affairs to guide and support advancement of OmniAntigen™ Platform (OAP) programs OAP enables systematic immune reprogramming therapy ( [...]
Ovid Therapeutics to Participate in Upcoming Investor Conferences
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today [...]
SpyGlass Pharma to Participate in Upcoming Investor Conferences
05/11/2026
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management [...]
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
05/11/2026
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Science 37 Named 2026 “BioTechnology Innovation of the Year” for its Direct-to-Patient Clinical Trial Delivery Model
05/11/2026
The BioTech Breakthrough Award recognizes Science 37’s Direct-to-Patient Site model for expanding patient access and delivering measurable clinical trial performance nationwide MORRISVILLE, N.C., Nov. 05, 2026 (GLOBE [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
05/11/2026
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment [...]
Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
05/11/2026
New direct practice expense supply code supports more consistent valuation of CPT 0563T MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an [...]
VeonGen Announces FDA Alignment on Pivotal Phase 3 Development and Clinical Progress of VG801 for Stargardt Disease
05/11/2026
FDA alignment on pivotal Phase 3 study design and CMC strategy marks an important milestone in VG801’s clinical development VG801 demonstrates consistent and sustained functional improvements through Month 12 across [...]
Nova Anchora Announces $23 Million Financing to Advance Topical Collagen VII Therapy for Dystrophic Epidermolysis Bullosa
05/11/2026
Financing led by Viking Global Investors alongside a syndicate of venture philanthropy investors with deep expertise in epidermolysis bullosa Proceeds to support scale-up manufacturing, IND-enabling development of NvA- [...]
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
05/11/2026
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Incyclix Bio Establishes Steering Committee of Leading Breast Cancer Experts to Guide INX-315 Clinical Development
05/11/2026
Appointment of distinguished oncology leaders comes as Incyclix prepares for a potential pivotal trial in 2027 RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell [...]
Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
05/11/2026
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
LightSolver Secures ~$1.8 Million Grant from Israel’s Innovation Authority to Advance its Laser Processing Unit (LPU)
05/11/2026
Government-backed R&D program to advance next-generation LPU hardware and expand the LPU Lab platform Builds on LightSolver’s recent commercial and technical momentum, including the strategic partnership with Boeing [...]
Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the [...]
Annovis Announces Pricing of $21.0 Million Public Offering
05/11/2026
MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
05/11/2026
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7 [...]
Ethris Reports Positive Topline Phase 2a Data for Nasal mRNA Candidate ETH47 in Asthma Patients Challenged with Rhinovirus
05/11/2026
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replication Exposure-response relationship observed, with greater interferon lambda (IFNλ) exposure associated with greater antiviral and [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum